Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date

Lily Dasso, Tala Al-Khaled, Sriram Sonty, Ahmad A Aref Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA Abstract: Netarsudil ophthalmic solution is a novel topical intraocular pressure (IO...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Dasso L, Al-Khaled T, Sonty S, Aref AA
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Glaucoma Treatment Rho-kinase Intraocular Pressure Lowering Glaucoma Medical Therapy Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/3da6654579ac40959f58e00c6181e007
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3da6654579ac40959f58e00c6181e007
record_format	dspace
spelling	oai:doaj.org-article:3da6654579ac40959f58e00c6181e0072021-12-02T08:34:42ZProfile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date1177-5483https://doaj.org/article/3da6654579ac40959f58e00c6181e0072018-10-01T00:00:00Zhttps://www.dovepress.com/profile-of-netarsudil-ophthalmic-solution-and-its-potential-in-the-tre-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Lily Dasso, Tala Al-Khaled, Sriram Sonty, Ahmad A Aref Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA Abstract: Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. Its unique pharmacology allows for IOP lowering as a result of direct reduction in trabecular outflow resistance in addition to a decrease in episcleral venous pressure and aqueous humor production. The efficacy of netarsudil has been shown in animal studies and human clinical trials. It has been shown to be noninferior to the therapy with topical timolol in individuals with baseline IOP <25 mmHg. Importantly, netarsudil has been shown to reduce IOP to the same degree, regardless of baseline levels. There are no known systemic safety issues associated with netarsudil. The most common local adverse effects relate to conjunctival hyperemia. The once-daily dosing schedule is advantageous for individuals who have difficulties with medication adherence. Further studies of a combination of netarsudil and latanoprost agents are currently underway. Keywords: glaucoma treatment, Rho kinase, intraocular pressure lowering, glaucoma medical therapyDasso LAl-Khaled TSonty SAref AADove Medical PressarticleGlaucoma TreatmentRho-kinaseIntraocular Pressure LoweringGlaucoma Medical TherapyOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 1939-1944 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Glaucoma Treatment Rho-kinase Intraocular Pressure Lowering Glaucoma Medical Therapy Ophthalmology RE1-994
spellingShingle	Glaucoma Treatment Rho-kinase Intraocular Pressure Lowering Glaucoma Medical Therapy Ophthalmology RE1-994 Dasso L Al-Khaled T Sonty S Aref AA Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
description	Lily Dasso, Tala Al-Khaled, Sriram Sonty, Ahmad A Aref Department of Ophthalmology and Visual Sciences, Illinois Eye & Ear Infirmary, University of Illinois at Chicago College of Medicine, Chicago, IL, USA Abstract: Netarsudil ophthalmic solution is a novel topical intraocular pressure (IOP)-lowering agent that has recently been approved by the US Food and Drug Administration (FDA) for the treatment of ocular hypertension and open-angle glaucoma. Its unique pharmacology allows for IOP lowering as a result of direct reduction in trabecular outflow resistance in addition to a decrease in episcleral venous pressure and aqueous humor production. The efficacy of netarsudil has been shown in animal studies and human clinical trials. It has been shown to be noninferior to the therapy with topical timolol in individuals with baseline IOP <25 mmHg. Importantly, netarsudil has been shown to reduce IOP to the same degree, regardless of baseline levels. There are no known systemic safety issues associated with netarsudil. The most common local adverse effects relate to conjunctival hyperemia. The once-daily dosing schedule is advantageous for individuals who have difficulties with medication adherence. Further studies of a combination of netarsudil and latanoprost agents are currently underway. Keywords: glaucoma treatment, Rho kinase, intraocular pressure lowering, glaucoma medical therapy
format	article
author	Dasso L Al-Khaled T Sonty S Aref AA
author_facet	Dasso L Al-Khaled T Sonty S Aref AA
author_sort	Dasso L
title	Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
title_short	Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
title_full	Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
title_fullStr	Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
title_full_unstemmed	Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
title_sort	profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/3da6654579ac40959f58e00c6181e007
work_keys_str_mv	AT dassol profileofnetarsudilophthalmicsolutionanditspotentialinthetreatmentofopenangleglaucomaevidencetodate AT alkhaledt profileofnetarsudilophthalmicsolutionanditspotentialinthetreatmentofopenangleglaucomaevidencetodate AT sontys profileofnetarsudilophthalmicsolutionanditspotentialinthetreatmentofopenangleglaucomaevidencetodate AT arefaa profileofnetarsudilophthalmicsolutionanditspotentialinthetreatmentofopenangleglaucomaevidencetodate
_version_	1718398449755357184

Profile of netarsudil ophthalmic solution and its potential in the treatment of open-angle glaucoma: evidence to date

Ejemplares similares